SWK Holdings focuses on pharmaceutical development, manufacturing and intellectual property licensing business. Co.'s reportable segments include: Finance Receivables and Pharmaceutical Development. Co.'s Finance Receivables segment is primarily focused on commercial-stage products and related intellectual property through royalty purchases and financings, as well as its commercialized products. Co. engages in Pharmaceutical Development segment through its subsidiary, Enteris BioPharma, Inc. (Enteris). Enteris is a clinical stage biopharmaceutical company providing formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. The SWKH stock yearly return is shown above.
The yearly return on the SWKH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SWKH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|